These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19719457)

  • 1. Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
    Sissung TM; Thordardottir S; Gardner ER; Figg WD
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1058-69. PubMed ID: 19719457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of thalidomide and its role in the treatment of metastatic prostate cancer.
    Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S49-57. PubMed ID: 12850527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.
    Tohnya TM; Ng SS; Dahut WL; Wright JJ; Arlen PM; Gulley JL; Parker C; Zeldis J; Figg WD
    Clin Prostate Cancer; 2004 Mar; 2(4):241-3. PubMed ID: 15072608
    [No Abstract]   [Full Text] [Related]  

  • 4. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
    Zabransky DJ; Smith HA; Thoburn CJ; Zahurak M; Keizman D; Carducci M; Eisenberger MA; McNeel DG; Drake CG; Antonarakis ES
    Prostate; 2012 Apr; 72(5):487-98. PubMed ID: 21748755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
    Keizman D; Zahurak M; Sinibaldi V; Carducci M; Denmeade S; Drake C; Pili R; Antonarakis ES; Hudock S; Eisenberger M
    Clin Cancer Res; 2010 Nov; 16(21):5269-76. PubMed ID: 20978144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide: the emerging role of a novel targeted agent in malignancies.
    Kalmadi S; Baz R; Mahindra A
    Drugs Today (Barc); 2007 Feb; 43(2):85-95. PubMed ID: 17353946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of lenalidomide in hematological malignancies.
    Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A
    J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide analogues as anticancer drugs.
    Aragon-Ching JB; Li H; Gardner ER; Figg WD
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):167-74. PubMed ID: 17975653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide: a synthetic compound with an evolving role in cancer management.
    Saloura V; Grivas PD
    Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer.
    Capitosti SM; Hansen TP; Brown ML
    Bioorg Med Chem; 2004 Jan; 12(2):327-36. PubMed ID: 14723953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
    Bodera P; Stankiewicz W
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):192-6. PubMed ID: 21913886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in solid tumors.
    Segler A; Tsimberidou AM
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1393-406. PubMed ID: 22584909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide - current understanding of mechanistic properties.
    Tageja N
    Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.
    Sundaresan L; Kumar P; Chatterjee S
    Future Oncol; 2018 Oct; 14(23):2383-2401. PubMed ID: 30141351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Galanina N; Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
    Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
    Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.